FluGen lands $7.8 million shot of investment capital
FluGen Inc. has landed $7.8 million that should help bring one of its leading technologies into human clinical trials this year. Madison-based FluGen will use the money to fund a Phase I clinical trial for its vaccine delivery device, a poker chip-sized, micro-needle skin patch the company says is more effective and less painful than standard needle injections. FluGen will use a vaccine that's already on the market in the trial, said Paul Radspinner, president and chief executive officer. (MILWAUKEE JOURNAL SENTINEL, 2/22)
To access this content, you must purchase a Premium membership, or log in if you are a member.
